论文部分内容阅读
目的:探讨苯氨氯地平联合替米沙坦治疗高血压病的疗效与安全性。方法:经过4周单用氨氯地平5 mg洗脱期后,共有未达标的高血压病患者128例入选,随机分组,分别给予氨氯地平5 mg加替米沙坦80 mg及氨氯地平10 mg各64例,治疗8周后观察2组的疗效及不良反应。结果:两组患者治疗4周后血压均较入选前有明显改善,治疗前后比较差异具有统计学意义。氨氯地平和替米沙坦联合治疗组收缩压总有效率为92.2%,单用氨氯地平组收缩压75%,两者比较差异有统计学意义(P<0.05)。氨氯地平和替米沙坦联合组不良反应发生率为1.6%,单用氨氯地平组12.5%,两组间比较有统计学差异(P<0.05)。结论:氨氯地平联合替米沙坦具有更明显的降压作用,且不良反应较少。
Objective: To investigate the efficacy and safety of benamlodipine and telmisartan in the treatment of hypertension. Methods: After 4 weeks of single amlodipine 5 mg elution period, a total of 128 patients with unqualified hypertension were enrolled and randomized to receive amlodipine 5 mg plus telmisartan 80 mg and amlodipine 64 cases of 10 mg each. After 8 weeks of treatment, the curative effect and adverse reactions of the two groups were observed. Results: After 4 weeks of treatment, the blood pressure of the two groups of patients was significantly improved compared with that before the treatment. The difference between before and after treatment was statistically significant. Amlodipine and telmisartan combined treatment group, the total effective rate of systolic blood pressure was 92.2%, with amlodipine alone 75% systolic blood pressure, the difference was statistically significant (P <0.05). The incidence of adverse reactions was 1.6% in amlodipine and telmisartan groups, and 12.5% in amlodipine alone group. There was a significant difference between the two groups (P <0.05). Conclusion: Amlodipine combined with telmisartan has a more obvious antihypertensive effect with less adverse reactions.